Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dainippon Sumitomo Pharma seeks approval in Japan for Surepost in combination therapy

April 17, 2012

Biodel selects ultrarapid-acting insulin formulation to advance to phase II testing

April 16, 2012

GSK AMPK activators are active in diabetes and obesity models

April 16, 2012

New melanin-concentrating hormone receptor antagonists identified

April 16, 2012

Joint research for metabolic disease therapies advances

April 13, 2012

Lilly obtains approval in Canada for testosterone replacement therapy

April 12, 2012

Orphan drug status granted to ReGenX BioSciences program

April 12, 2012

New glucagon GLP-1 receptor agonists designed in China

April 12, 2012

Korlym now available in U.S.

April 11, 2012

Pharmos reports promising data from ongoing phase IIa trial of levotofisopam

April 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...